Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs
pixabay.com
ARDS causes a life-threatening damage to the lungs induced by an excessive hyperinflammatory reaction of the lung tissue in response to bacterial and viral infections including SARS-CoV2 (COVID-19). No targeted therapy is available for this syndrome to prevent fluid retention and tissue damage to the lungs. Pantherna Therapeutics is developing a targeted therapy with a new mode of action by expressing a TIE-2 receptor agonist to restore endothelial barrier function.
"The new funds will be used to expand the PAN004 development activities and will also support Pantherna´s efforts to strengthen its R&D team and activities for advancing its mRNA therapeutics technology for new indications", Dr. Jörg Kaufmann, CSO at Pantherna Therapeutics.
"Qiagen developed the purification of RNA nearly 40 years ago, and in recent years the outstanding impact of mRNA-technology for vaccination became obvious. I am more than happy to follow now the development of mRNA-technology to the urgent need of targeted therapy", Prof. Detlev Riesner, Qiagen-co-founder and private investor of several Biotech companies.
"We are delighted to assist in the new funding round to bring Pantherna´s innovation a huge step closer to the clinic", Dr. Anke Caßing, Principal at High-Tech Gründerfonds.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.